{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins represented in immunopeptidome",
      "value": "62.3%",
      "comparator_or_baseline": "37.3% (comparator)",
      "interpretation": "Intratumoral mRNA vaccination produced a broader antigen display, representing a 25 percentage point increase in detectable tumor proteins.",
      "evidence_line_refs": ["L28"]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins represented in MHC-I peptidome",
      "value": "40.6%",
      "comparator_or_baseline": "20.6% (comparator)",
      "interpretation": "Strong expansion of MHC-I presented peptide landscape after vaccination, nearly doubling the representation of tumor proteins for T-cell recognition.",
      "evidence_line_refs": ["L29"]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01",
      "comparator_or_baseline": "N/A (statistical test)",
      "interpretation": "Vaccinated subgroup demonstrated statistically significant improved survival under ICI treatment compared to unvaccinated patients.",
      "evidence_line_refs": ["L30"]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score (normalized units)",
      "value": "3.1",
      "comparator_or_baseline": "1.0 (baseline)",
      "interpretation": "Marked 3.1-fold induction of type I interferon signaling in tumor tissue after mRNA vaccination, indicating robust innate immune activation.",
      "evidence_line_refs": ["L31"]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change in tumor tissue",
      "value": "2.4x",
      "comparator_or_baseline": "1.0x (baseline)",
      "interpretation": "Vaccination increased PD-L1 expression 2.4-fold, making the checkpoint axis more targetable for anti-PD-L1 therapy.",
      "evidence_line_refs": ["L32"]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x",
      "comparator_or_baseline": "1.0x (baseline)",
      "interpretation": "Combined therapy resulted in 1.8-fold increased CD8+ T-cell infiltration, indicating enhanced immune cell recruitment to tumors.",
      "evidence_line_refs": ["L33"]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models, indicating that mRNA vaccination alone is insufficient for therapeutic effect.",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment had limited activity in low-immunogenic baseline settings, demonstrating that checkpoint blockade alone cannot overcome poor immunogenicity.",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect, confirming that the mRNA component is essential for observed biological activity.",
      "evidence_line_ref": "L38"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, demonstrating that interferon signaling is mechanistically required for the effect.",
      "evidence_line_ref": "L39"
    }
  ]
}